Why the study?
Although randomized controlled trials found no overall benefit from adding invasive endovascular treatments to optimized medical therapy in atherosclerotic renal artery stenosis (ARAS), trial design limitations do not rule out benefits in carefully selected patients. Defining the diagnostic and therapeutic landscape is needed to identify appropriate treatment modalities based on clinical presentation.
What are the optimal diagnostic modalities and treatment strategies (medical therapy versus selective endovascular or surgical revascularization) for managing patients with atherosclerotic renal artery stenosis across different clinical presentations?
What are the optimal diagnostic modalities and treatment strategies (medical therapy versus selective endovascular or surgical revascularization) for managing patients with atherosclerotic renal artery stenosis across different clinical presentations?
Answers are grounded in this paper and cite their sources.
This narrative review synthesizes evidence on the diagnosis and management of atherosclerotic renal artery stenosis, affirming optimized medical therapy as the initial standard of care while supporting selective endovascular revascularization for high-risk phenotypes such as recurrent flash pulmonary edema, refractory hypertension, and rapidly declining renal function.
Atherosclerotic renal artery stenosis (ARAS) is a significant cause of secondary hypertension and kidney injury with important cardiovascular consequences. This review briefly discusses the pathophysiology of ARAS, evaluates in-depth the diagnostic performance of duplex ultrasound, computed tomography angiography, and magnetic resonance angiography, and synthesizes results from major randomized trials and observational studies to explore current treatment options. The objective is to define the current diagnostic and therapeutic landscape of ARAS in a manner that supports evidence-based clinical decision making, and identify which treatment modality may be appropriate based on clinical presentation. The preference for optimized medical therapy as the initial standard of care is largely based on multiple randomized controlled trials (RCTs), which found no overall benefit from invasive endovascular treatments in conjunction with medical therapy. However, the limitations in trial design indicate that these results do not rule out the benefit in carefully selected patients. Evidence from subgroup analyses and non-randomized studies supports invasive endovascular revascularization in presentations such as recurrent flash pulmonary edema, progressive decline in renal function, and hypertension resistant to pharmacologic medical therapy. Endovascular stenting is preferred when anatomy is favorable, while open surgical reconstruction, including aortorenal bypass or endarterectomy, is reserved for complex lesions, failed prior endovascular intervention, or concomitant aortic surgery. The review also discusses emerging strategies, including novel stent platforms and drug-eluting technology, which may improve outcomes if validated in targeted high-risk cohorts.
No takes yet. Share an insight, caveat, or question.
Ahmed et al. (2026) conducted a review in Atherosclerotic renal artery stenosis (ARAS). Endovascular revascularization (PTRA/PTRAS) or open surgical reconstruction vs. Optimized pharmacological medical therapy alone was evaluated on Cardiovascular and renal events, blood pressure control, and renal function preservation.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: